In vivo, [61Cu]Cu-NODAGA-PSMA-I&T showed clear superiority over [61Cu]Cu-DOTAGA-PSMA-I&T by means of higher tumor uptake (P = 0.0050 1 h after injection vs. P = 0.0066 4 h after injection), lower blood-pool activity, and especially liver and abdominal activity. The gene discussed is FOLH1; the disease is neoplasm.